SNDX
Syndax Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology · US
$14.15
−1.19%Oct 26, 2026, 11:00 UTC
Syndax Pharmaceuticals Inc announced that it will report its third-quarter 2026 financial results and provide a business update on November 2, 2026.
Source:Oct 14, 2026, 14:56 UTC
Syndax Pharmaceuticals Inc shares fell 16%.
Source:Oct 14, 2026, 02:17 UTC
Syndax Pharmaceuticals Inc shares fell more than 11% after its Phase 2 MAXPIRe trial of axatilimab missed its primary endpoint in idiopathic pulmonary fibrosis.
Source:Oct 13, 2026, 14:43 UTC
Syndax Pharmaceuticals Inc said it would not continue developing axatilimab for idiopathic pulmonary fibrosis.
Oct 13, 2026, 12:02 UTC
Syndax Pharmaceuticals Inc shares fell sharply in pre-market trading.
Source:Oct 12, 2026, 20:01 UTC
Syndax Pharmaceuticals Inc announced that its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet the primary endpoint of annualized forced vital capacity decline; the treatment was well tolerated, with no new safety signals.
Oct 2, 2026, 20:01 UTC
Syndax Pharmaceuticals granted inducement stock options to purchase up to 213,300 shares of common stock to nine new employees on October 1, 2026.
Source:Aug 4, 2026, 20:01 UTC
Syndax Pharmaceuticals reported second quarter 2026 financial results, with total revenue of $73 million, a 92% year-over-year increase.
Jul 14, 2026, 20:03 UTC
Syndax Pharmaceuticals introduced two pipeline assets aimed at non-small cell lung cancer and myelofibrosis at a company R&D event.
Source:Jun 10, 2026, 00:00 UTC
Syndax Pharmaceuticals issued $250.0 million of 2.25% Convertible Senior Notes due 2031, with net proceeds of approximately $243.0 million for general corporate purposes.
Jun 4, 2026, 00:00 UTC
Syndax Pharmaceuticals Inc completed a private placement of $250 million 2.25% convertible senior notes due 2031 on June 10, 2026.
Source: